{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:20:50Z","timestamp":1791595250448,"version":"4.3.4"},"reference-count":27,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2011,1,14]],"date-time":"2011-01-14T00:00:00Z","timestamp":1294963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Exper Ophthalmology"],"published-print":{"date-parts":[[2011,5]]},"abstract":"<jats:title>A<jats:sc>bstract<\/jats:sc><\/jats:title><jats:p><jats:bold>Background:\u2002<\/jats:bold> Interferons are currently used for hepatitis B and C virus infection; the effect of interferons against adenovirus has not been elucidated. It has been reported that interferon\u2010\u03b2 and interferon\u2010\u03b3 were effective against adenovirus serotype 3. We investigated the anti\u2010adenoviral effect of interferon\u2010\u03b2 and interferon\u2010\u03b3 in serotypes that cause acute keratoconjunctivitis, using quantitative polymerase chain reaction <jats:italic>in vitro<\/jats:italic>.<\/jats:p><jats:p><jats:bold>Design:\u2002<\/jats:bold> Experimental study carried out in a university.<\/jats:p><jats:p><jats:bold>Samples:\u2002<\/jats:bold> Five strains of different serotypes of adenovirus, types 3 (AdV3; species B), 4 (species E), 8, 19a and 37 (species D) and interferon\u2010\u03b2 and interferon\u2010\u03b3 for <jats:italic>in vitro<\/jats:italic> assay.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> After pretreatment of A549 with serial dilution of interferons for 24\u2003h, adenovirus was cultivated for 7\u2003days, and adenoviral DNA was quantitatively measured by real\u2010time polymerase chain reaction.<\/jats:p><jats:p><jats:bold>Main Outcome Measures:\u2002<\/jats:bold> Number of virus copies after treatment and the 50% effective concentration (EC<jats:sub>50<\/jats:sub>).<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> Interferon\u2010\u03b2 showed a dose\u2010dependent inhibitory effect on all serotypes. EC<jats:sub>50<\/jats:sub> of interferon\u2010\u03b2 ranged between 211 and 843\u2003IU\/mL. A similar tendency was observed with interferon\u2010\u03b3. EC<jats:sub>50<\/jats:sub> of interferon\u2010\u03b3 ranged between 133 and 9130\u2003IU\/mL. Among the serotypes, interferon\u2010\u03b3 exhibited the greatest inhibitory effect on AdV37. In contrast, AdV4 showed the lowest sensitivity to interferon\u2010\u03b3. Statistically significant dose dependency for both interferon\u2010\u03b2 and interferon\u2010\u03b3 was observed in several serotypes.<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> These results suggest that both interferon\u2010\u03b2 and interferon\u2010\u03b3 have anti\u2010adenoviral activity <jats:italic>in vitro<\/jats:italic>. Interferons have the potential to be used for local treatment of adenoviral keratoconjunctivitis, although further evaluation in animal models and clinical trials is necessary.<\/jats:p>","DOI":"10.1111\/j.1442-9071.2010.02457.x","type":"journal-article","created":{"date-parts":[[2010,11,11]],"date-time":"2010-11-11T13:14:48Z","timestamp":1289481288000},"page":"358-363","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Anti\u2010adenoviral effect of interferon\u2010\u03b2 and interferon\u2010\u03b3 in serotypes that cause acute keratoconjunctivitis"],"prefix":"10.1111","volume":"39","author":[{"given":"Eiichi","family":"Uchio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotoshi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aki","family":"Fuchigami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Kadonosono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,1,14]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"121","article-title":"Antiviral chemotherapy: in vitro activity of ribavirin on DNA and RNA viruses","volume":"24","author":"Lagrota MH","year":"1982","journal-title":"Rev Latinoam Microbiol"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1978.03910060288022"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-3542(91)90054-U"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)36149-9"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/426594"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-006-0523-z"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2004.00204.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2005.09.024"},{"key":"e_1_2_6_10_2","first-page":"201","article-title":"Efficacy of long\u2010term interferon therapy in chronic hepatitis B patients with HBV genotype C","volume":"10","author":"Sakai T","year":"2002","journal-title":"Int J Mol Med"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2008.10.056"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1253\/jcj.64.321"},{"key":"e_1_2_6_13_2","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1128\/iai.41.1.214-218.1983","article-title":"Antibody and interferon act synergistically to inhibit enterovirus, adenovirus, and herpes simplex virus infection","volume":"41","author":"Langford MP","year":"1983","journal-title":"Infect Immun"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-68-3-941"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02334177"},{"key":"e_1_2_6_16_2","first-page":"43","article-title":"Ten years experience with human fibroblast interferon treatment of viral ophthalmic infections","volume":"11","author":"Romano A","year":"1988","journal-title":"Metab Pediatr Syst Ophthalmol"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.2068"},{"key":"e_1_2_6_18_2","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1128\/iai.27.2.292-296.1980","article-title":"Restriction endonucleases in identification of a genome type of adenovirus 19 associated with keratoconjunctivitis","volume":"27","author":"Wadell G","year":"1980","journal-title":"Infect Immun"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01603-06"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0022172400066365"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.37.12.3940-3945.1999"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.009225-0"},{"key":"e_1_2_6_23_2","doi-asserted-by":"crossref","first-page":"6204","DOI":"10.1128\/jvi.71.8.6204-6207.1997","article-title":"Integrin alpha5beta1\u2010mediated adenovirus infection is enhanced by the integrin\u2010activating antibody TS2\/16","volume":"71","author":"Davison E","year":"1997","journal-title":"J Virol"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1053\/plac.2001.0749"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.77.10.5928"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1006\/viro.2001.0967"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1006\/viro.2002.1359"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2004.07.018"}],"container-title":["Clinical &amp; Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1442-9071.2010.02457.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1442-9071.2010.02457.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T15:25:10Z","timestamp":1697383510000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1442-9071.2010.02457.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,14]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["10.1111\/j.1442-9071.2010.02457.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1442-9071.2010.02457.x","archive":["Portico"],"relation":{},"ISSN":["1442-6404","1442-9071"],"issn-type":[{"value":"1442-6404","type":"print"},{"value":"1442-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,14]]},"assertion":[{"value":"2011-01-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}